Sign up
Pharma Capital
EPIC: LANDO
Market: PRIVATE-NA
Sector: Pharma & Biotech

Landos Biopharma (PRIVATE): An emerging biopharmaceutical company focused on discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases.

Landos Biopharma

landosbiopharma.com

Interactive graph

col 3
col 4
col 5
col 6

Landos Biopharma Snapshot

Landos Biopharma, Inc. is an emerging biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, locally-acting small molecule targeting inflammatory bowel disease (IBD) that is expected to enter clinical testing for Crohn’s disease in 2018. Landos also has a robust pipeline of compounds for other autoimmune diseases. Landos is headquartered in Blacksburg, VA. For more information, please visit www.landosbiopharma.com  contact [email protected] or follow the company on Twitter at @LandosBio

View full LANDO profile View Profile
View All

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.